(Reuters) – Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc&rsquos Inlyta met the primary goals of a late-stage study in sufferers with the most common type of kidney cancer.
FILE PHOTO: The Merck logo is observed at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
The mixture resulted in statistically considerable and clinically meaningful improvements in general survival of the individuals and helped sufferers survive without having the cancer worsening, when compared to Pfizer&rsquos kidney cancer drug, Sutent.
Keytruda is a blockbuster medicine that targets a blockade of proteins recognized as PD-1 and is authorized for a range of other cancers, including lung cancer.
Pfizer&rsquos Inlyta is currently authorized to treat sophisticated renal cell cancer in patients who have faced failure of a single prior systemic therapy.
&ldquoThis marks the very first time that mixture therapy with an anti-PD-1 therapy has accomplished the dual principal endpoints of all round survival and progression-free survival as first-line therapy (in renal cell cancer patients),&rdquo Roger Perlmutter, president of Merck Research Laboratories said.
Reporting by Manas Mishra in Bengaluru
Published at Thu, 18 Oct 2018 11:27:14 +0000